Clarification of P-glycoprotein inhibition-related drug–drug interaction risks based on a literature search of the clinical information

References

• Alffenaar JW, Nienhuis WA, de Velde F, et al. (2010). Pharmacokinetics of rifampin and clarithromycin in patients treated for Mycobacterium ulcerans infection. Antimicrob Agents Chemother 54:3878–83
   PubMed Web of Science ®Google Scholar
• Amsden GW, Nafziger AN, Foulds G, Cabelus LJ. (2000). A study of the pharmacokinetics of azithromycin and nelfinavir when coadministered in healthy volunteers. J Clin Pharmacol 40:1522–7
   PubMed Web of Science ®Google Scholar
• Annaert P, Ye ZW, Stieger B, Augustijns P. (2010). Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1. Xenobiotica 40:163–76
   PubMed Web of Science ®Google Scholar
• Asberg A, Hartmann A, Fjeldsa E, et al. (2001). Bilateral pharmacokinetic interaction between cyclosporine A and atorvastatin in renal transplant recipients. Am J Transplant 1:382–6
   PubMed Web of Science ®Google Scholar
• Baris N, Kalkan S, Guneri S, et al. (2006). Influence of carvedilol on serum digoxin levels in heart failure: is there any gender difference? Eur J Clin Pharmacol 62:535–8
   PubMed Web of Science ®Google Scholar
• Beringer PM, Kriengkauykiat J, Zhang X, et al. (2008). Lack of effect of P-glycoprotein inhibition on renal clearance of dicloxacillin in patients with cystic fibrosis. Pharmacotherapy 28:883–94
   PubMed Web of Science ®Google Scholar
• Boffito M, Kurowski M, Kruse G, et al. (2004). Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimen. AIDS 18:1291–7
   PubMed Web of Science ®Google Scholar
• Boffito M, Maitland D, Dickinson L, et al. (2006). Pharmacokinetics of saquinavir hard-gel/ritonavir and atazanavir when combined once daily in HIV Type 1-infected individuals administered different atazanavir doses. AIDS Res Hum Retroviruses 22:749–56
   PubMed Web of Science ®Google Scholar
• Brandhorst G, Tenderich G, Zittermann A, et al. (2008). Everolimus exposure in cardiac transplant recipients is influenced by concomitant calcineurin inhibitor. Ther Drug Monit 30:113–16
   PubMed Web of Science ®Google Scholar
• Buss N, Snell P, Bock J, et al. (2001). Saquinavir and ritonavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatin capsules) administration. Br J Clin Pharmacol 52:255–64
   PubMed Web of Science ®Google Scholar
• Cao YJ, Flexner CW, Dunaway S, et al. (2008). Effect of low-dose ritonavir on the pharmacokinetics of the CXCR4 antagonist AMD070 in healthy volunteers. Antimicrob Agents Chemother 52:1630–4
   PubMed Web of Science ®Google Scholar
• Cha YJ, Lee H, Gu N, et al. (2013). Sustained increase in the oral bioavailability of loperamide after a single oral dose of HM30181, a P-glycoprotein inhibitor, in healthy male participants. Basic Clin Pharmacol Toxicol 113:419--24
   Google Scholar
• Chittick GE, Zong J, Blum MR, et al. (2006). Pharmacokinetics of tenofovir disoproxil fumarate and ritonavir-boosted saquinavir mesylate administered alone or in combination at steady state. Antimicrob Agents Chemother 50:1304–10
   PubMed Web of Science ®Google Scholar
• Choi DH, Chung JH, Choi JS. (2010). Pharmacokinetic interaction between oral lovastatin and verapamil in healthy subjects: role of P-glycoprotein inhibition by lovastatin. Eur J Clin Pharmacol 66:285–90
   PubMed Web of Science ®Google Scholar
• Choi DH, Shin WG, Choi JS. (2008). Drug interaction between oral atorvastatin and verapamil in healthy subjects: effects of atorvastatin on the pharmacokinetics of verapamil and norverapamil. Eur J Clin Pharmacol 64:445–9
   PubMed Web of Science ®Google Scholar
• Clucas AT, Shah A, Zhang YD, et al. (2007). Phase I evaluation of the safety, pharmacokinetics and pharmacodynamics of CP-481,715. Clin Pharmacokinet 46:757–66
   PubMed Web of Science ®Google Scholar
• Croft M, Keely B, Morris I, et al. (2012). Predicting drug candidate victims of drug-drug interactions, using microdosing. Clin Pharmacokinet 51:237–46
   PubMed Web of Science ®Google Scholar
• Davis MW, Wason S. (2014). Effect of steady-state atorvastatin on the pharmacokinetics of a single dose of colchicine in healthy adults under fasted conditions. Clin Drug Investig 34:259–67
   PubMed Web of Science ®Google Scholar
• Delavenne X, Ollier E, Basset T, et al. (2013). A semi-mechanistic absorption model to evaluate drug-drug interaction with dabigatran: application with clarithromycin. Br J Clin Pharmacol 76:107–13
   PubMed Web of Science ®Google Scholar
• Dorani H, Schutzer KM, Sarich TC, et al. (2007). Pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor ximelagatran co-administered with different classes of antibiotics in healthy volunteers. Eur J Clin Pharmacol 63:571–81
   PubMed Web of Science ®Google Scholar
• Dumond JB, Vourvahis M, Rezk NL, et al. (2010). A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir. Clin Pharmacol Ther 87:735–42
   PubMed Web of Science ®Google Scholar
• Elsby R, Gillen M, Butters C, et al. (2011). The utility of in vitro data in making accurate predictions of human P-glycoprotein-mediated drug-drug interactions: a case study for AZD5672. Drug Metab Dispos 39:275–82
   PubMed Web of Science ®Google Scholar
• EMA. (2012). Guideline on the investigation of drug interactions. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/07/WC500129606.pdf
   Google Scholar
• Eriksson UG, Dorani H, Karlsson J, et al. (2006). Influence of erythromycin on the pharmacokinetics of ximelagatran may involve inhibition of P-glycoprotein-mediated excretion. Drug Metab Dispos 34:775–82
   PubMed Web of Science ®Google Scholar
• FDA. (2012). Drug interaction studies – study design, data analysis, implications for dosing, and labeling recommendations. Draft Guidance. Available from: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm292362.pdf
   Google Scholar
• Fenner KS, Troutman MD, Kempshall S, et al. (2009). Drug-drug interactions mediated through P-glycoprotein: clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug. Clin Pharmacol Ther 85:173–81
   PubMed Web of Science ®Google Scholar
• Frassetto L, Thai T, Aggarwal AM, et al. (2003). Pharmacokinetic interactions between cyclosporine and protease inhibitors in HIV+ subjects. Drug Metab Pharmacokinet 18:114–20
   PubMedGoogle Scholar
• Garg V, Chandorkar G, Farmer HF, et al. (2012). Effect of telaprevir on the pharmacokinetics of midazolam and digoxin. J Clin Pharmacol 52:1566–73
   PubMed Web of Science ®Google Scholar
• Garg V, van Heeswijk R, Lee JE, et al. (2011). Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 54:20–7
   PubMed Web of Science ®Google Scholar
• Giacomini KM, Huang SM, Tweedie DJ, et al. (2010). Membrane transporters in drug development. Nat Rev Drug Discov 9:215–36
   PubMed Web of Science ®Google Scholar
• Gupta S, Banfield C, Kantesaria B, et al. (2001). Pharmacokinetic and safety profile of desloratadine and fexofenadine when coadministered with azithromycin: a randomized, placebo-controlled, parallel-group study. Clin Ther 23:451–66
   PubMed Web of Science ®Google Scholar
• Gurley BJ, Barone GW, Williams DK, et al. (2006). Effect of milk thistle (Silybum marianum) and black cohosh (Cimicifuga racemosa) supplementation on digoxin pharmacokinetics in humans. Drug Metab Dispos 34:69–74
   PubMed Web of Science ®Google Scholar
• Gurley BJ, Swain A, Barone GW, et al. (2007). Effect of goldenseal (Hydrastis canadensis) and kava kava (Piper methysticum) supplementation on digoxin pharmacokinetics in humans. Drug Metab Dispos 35:240–5
   PubMed Web of Science ®Google Scholar
• Gurley BJ, Swain A, Williams DK, et al. (2008). Gauging the clinical significance of P-glycoprotein-mediated herb-drug interactions: comparative effects of St. John’s wort, Echinacea, clarithromycin, and rifampin on digoxin pharmacokinetics. Mol Nutr Food Res 52:772–9
   PubMed Web of Science ®Google Scholar
• Hartter S, Sennewald R, Nehmiz G, Reilly P. (2013). Oral bioavailability of dabigatran etexilate (Pradaxa®) after co-medication with verapamil in healthy subjects. Br J Clin Pharmacol 75:1053–62
   PubMed Web of Science ®Google Scholar
• Hsyu PH, Schultz-Smith MD, Lillibridge JH, et al. (2001). Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin. Antimicrob Agents Chemother 45:3445–50
   PubMed Web of Science ®Google Scholar
• Ieiri I, Tsunemitsu S, Maeda K, et al. (2013). Mechanisms of pharmacokinetic enhancement between ritonavir and saquinavir; micro/small dosing tests using midazolam (CYP3A4), fexofenadine (p-glycoprotein), and pravastatin (OATP1B1) as probe drugs. J Clin Pharmacol 53:654–61
   PubMed Web of Science ®Google Scholar
• Jalava KM, Partanen J, Neuvonen PJ. (1997). Itraconazole decreases renal clearance of digoxin. Ther Drug Monit 19:609–13
   PubMed Web of Science ®Google Scholar
• Kaijser M, Johnsson C, Zezina L, et al. (1997). Elevation of cyclosporin A blood levels during carvedilol treatment in renal transplant patients. Clin Transplant 11:577–81
   PubMed Web of Science ®Google Scholar
• Kakuda TN, Abel S, Davis J, et al. (2011). Pharmacokinetic interactions of maraviroc with darunavir-ritonavir, etravirine, and etravirine-darunavir-ritonavir in healthy volunteers: results of two drug interaction trials. Antimicrob Agents Chemother 55:2290–6
   PubMed Web of Science ®Google Scholar
• Kalvass JC, Polli JW, Bourdet DL, et al. (2013). Why clinical modulation of efflux transport at the human blood-brain barrier is unlikely: the ITC evidence-based position. Clin Pharmacol Ther 94:80–94
   PubMed Web of Science ®Google Scholar
• Kantola T, Kivisto KT, Neuvonen PJ. (1998). Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 64:177–82
   PubMed Web of Science ®Google Scholar
• Kaukonen KM, Olkkola KT, Neuvonen PJ. (1997). Itraconazole increases plasma concentrations of quinidine. Clin Pharmacol Ther 62:510– 17
   PubMed Web of Science ®Google Scholar
• Khaliq Y, Gallicano K, Venance S, et al. (2000). Effect of ketoconazole on ritonavir and saquinavir concentrations in plasma and cerebrospinal fluid from patients infected with human immunodeficiency virus. Clin Pharmacol Ther 68:637–46
   PubMed Web of Science ®Google Scholar
• Kharasch ED, Bedynek PS, Hoffer C, et al. (2012). Lack of indinavir effects on methadone disposition despite inhibition of hepatic and intestinal cytochrome P4503A (CYP3A). Anesthesiology 116:432–47
   PubMed Web of Science ®Google Scholar
• Kharasch ED, Bedynek PS, Walker A, et al. (2008). Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities. Clin Pharmacol Ther 84:506–12
   PubMed Web of Science ®Google Scholar
• Kharasch ED, Hoffer C, Altuntas TG, Whittington D. (2004). Quinidine as a probe for the role of p-glycoprotein in the intestinal absorption and clinical effects of fentanyl. J Clin Pharmacol 44:224–33
   PubMed Web of Science ®Google Scholar
• Kharasch ED, Hoffer C, Whittington D, Sheffels P. (2003). Role of P-glycoprotein in the intestinal absorption and clinical effects of morphine. Clin Pharmacol Ther 74:543–54
   PubMed Web of Science ®Google Scholar
• Kharasch ED, Hoffer C, Whittington D, et al. (2009). Methadone pharmacokinetics are independent of cytochrome P4503A (CYP3A) activity and gastrointestinal drug transport: insights from methadone interactions with ritonavir/indinavir. Anesthesiology 110:660–72
   PubMed Web of Science ®Google Scholar
• Kharasch ED, Stubbert K. (2013). Cytochrome P4503A does not mediate the interaction between methadone and ritonavir-lopinavir. Drug Metab Dispos 41:2166–74
   PubMed Web of Science ®Google Scholar
• Kirby BJ, Collier AC, Kharasch ED, et al. (2012). Complex drug interactions of the HIV protease inhibitors 3: effect of simultaneous or staggered dosing of digoxin and ritonavir, nelfinavir, rifampin, or bupropion. Drug Metab Dispos 40:610–16
   PubMed Web of Science ®Google Scholar
• Kovarik JM, Rigaudy L, Guerret M, et al. (1999). Longitudinal assessment of a P-glycoprotein-mediated drug interaction of valspodar on digoxin. Clin Pharmacol Ther 66:391–400
   PubMed Web of Science ®Google Scholar
• Kovarik JM, Stitah S, Slade A, et al. (2010). Sotrastaurin and cyclosporine drug interaction study in healthy subjects. Biopharm Drug Dispos 31:331–9
   PubMed Web of Science ®Google Scholar
• Krishna R, Bergman A, Larson P, et al. (2007). Effect of a single cyclosporine dose on the single-dose pharmacokinetics of sitagliptin (MK-0431), a dipeptidyl peptidase-4 inhibitor, in healthy male subjects. J Clin Pharmacol 47:165–74
   PubMed Web of Science ®Google Scholar
• Kusuhara H, Miura M, Yasui-Furukori N, et al. (2013). Effect of coadministration of single and multiple doses of rifampicin on the pharmacokinetics of fexofenadine enantiomers in healthy subjects. Drug Metab Dispos 41:206–13
   PubMed Web of Science ®Google Scholar
• la Porte CJ, Li Y, Beique L, et al. (2007). The effect of ABCB1 polymorphism on the pharmacokinetics of saquinavir alone and in combination with ritonavir. Clin Pharmacol Ther 82:389–95
   PubMed Web of Science ®Google Scholar
• Lee J, Moy S, Meijer J, et al. (2013). Role of cytochrome p450 isoenzymes 3A and 2D6 in the in vivo metabolism of mirabegron, a β3-adrenoceptor agonist. Clin Drug Investig 33:429–40
   PubMed Web of Science ®Google Scholar
• Lee JE, van Heeswijk R, Alves K, et al. (2011). Effect of the hepatitis C virus protease inhibitor telaprevir on the pharmacokinetics of amlodipine and atorvastatin. Antimicrob Agents Chemother 55:4569–74
   PubMed Web of Science ®Google Scholar
• Lemahieu WP, Hermann M, Asberg A, et al. (2005). Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus. Am J Transplant 5:2236–43
   PubMed Web of Science ®Google Scholar
• Lemma GL, Wang Z, Hamman MA, et al. (2006). The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates. Clin Pharmacol Ther 79:218–30
   PubMed Web of Science ®Google Scholar
• Lilja JJ, Backman JT, Laitila J, et al. (2003). Itraconazole increases but grapefruit juice greatly decreases plasma concentrations of celiprolol. Clin Pharmacol Ther 73:192–8
   PubMed Web of Science ®Google Scholar
• Lilja JJ, Niemi M, Fredrikson H, Neuvonen PJ. (2007). Effects of clarithromycin and grapefruit juice on the pharmacokinetics of glibenclamide. Br J Clin Pharmacol 63:732–40
   PubMed Web of Science ®Google Scholar
• Ma JD, Tsunoda SM, Bertino JS Jr, et al. (2010). Evaluation of in vivo P-glycoprotein phenotyping probes: a need for validation. Clin Pharmacokinet 49:223–37
   PubMed Web of Science ®Google Scholar
• Machavaram KK, Gundu J, Yamsani MR. (2006). Effect of ketoconazole and rifampicin on the pharmacokinetics of ranitidine in healthy human volunteers: a possible role of P-glycoprotein. Drug Metabol Drug Interact 22:47–65
   PubMedGoogle Scholar
• Malingre MM, Richel DJ, Beijnen JH, et al. (2001a). Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel. J Clin Oncol 19:1160–6
   PubMed Web of Science ®Google Scholar
• Malingre MM, Ten Bokkel Huinink WW, Mackay M, et al. (2001b). Pharmacokinetics of oral cyclosporin A when co-administered to enhance the absorption of orally administered docetaxel. Eur J Clin Pharmacol 57:305–7
   PubMed Web of Science ®Google Scholar
• McCance-Katz EF, Moody DE, Smith PF, et al. (2006). Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir/ritonavir, and ritonavir. Clin Infect Dis 43(Suppl 4):S235–46
   Google Scholar
• Mendell J, Zahir H, Matsushima N, et al. (2013). Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor. Am J Cardiovasc Drugs 13:331–42
   PubMed Web of Science ®Google Scholar
• Misaka S, Miyazaki N, Yatabe MS, et al. (2013). Pharmacokinetic and pharmacodynamic interaction of nadolol with itraconazole, rifampicin and grapefruit juice in healthy volunteers. J Clin Pharmacol 53:738–45
   PubMed Web of Science ®Google Scholar
• Morris CA, Lopez-Lazaro L, Jung D, et al. (2012). Drug-drug interaction analysis of pyronaridine/artesunate and ritonavir in healthy volunteers. Am J Trop Med Hyg 86:489–95
   PubMed Web of Science ®Google Scholar
• Muck W, Mai I, Fritsche L, et al. (1999). Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients. Clin Pharmacol Ther 65:251–61
   PubMed Web of Science ®Google Scholar
• Nakagami T, Yasui-Furukori N, Saito M, et al. (2005). Effect of verapamil on pharmacokinetics and pharmacodynamics of risperidone: in vivo evidence of involvement of P-glycoprotein in risperidone disposition. Clin Pharmacol Ther 78:43–51
   PubMed Web of Science ®Google Scholar
• Niemi M, Tornio A, Pasanen MK, et al. (2006). Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide. Eur J Clin Pharmacol 62:463–72
   PubMed Web of Science ®Google Scholar
• Oswald S, Nassif A, Modess C, et al. (2010). Pharmacokinetic and pharmacodynamic interactions between the immunosuppressant sirolimus and the lipid-lowering drug ezetimibe in healthy volunteers. Clin Pharmacol Ther 87:663–7
   PubMed Web of Science ®Google Scholar
• Pedersen KE, Christiansen BD, Klitgaard NA, Nielsen-Kudsk F. (1983). Effect of quinidine on digoxin bioavailability. Eur J Clin Pharmacol 24:41–7
   PubMed Web of Science ®Google Scholar
• Penzak SR, Formentini E, Alfaro RM, et al. (2005). Prednisolone pharmacokinetics in the presence and absence of ritonavir after oral prednisone administration to healthy volunteers. J Acquir Immune Defic Syndr 40:573–80
   PubMed Web of Science ®Google Scholar
• Pescovitz MD, Bloom R, Pirsch J, et al. (2009). A randomized, double-blind, pharmacokinetic study of oral maribavir with tacrolimus in stable renal transplant recipients. Am J Transplant 9:2324–30
   PubMed Web of Science ®Google Scholar
• Pham PA, la Porte CJ, Lee LS, et al. (2009). Differential effects of tipranavir plus ritonavir on atorvastatin or rosuvastatin pharmacokinetics in healthy volunteers. Antimicrob Agents Chemother 53:4385–92
   PubMed Web of Science ®Google Scholar
• Philip DH, John RH. (2010). Top 100 drug interactions: a guide to patient management. Clearwater (FL): H&H Publications
   Google Scholar
• Potter JM, McWhinney BC, Sampson L, Hickman PE. (2004). Area-under-the-curve monitoring of prednisolone for dose optimization in a stable renal transplant population. Ther Drug Monit 26:408–14
   PubMed Web of Science ®Google Scholar
• Prakash J, Velpandian T, Pande JN, Gupta SK. (2003). Serum rifampicin levels in patients with tuberculosis: effect of P-glycoprotein and CYP3A4 blockers on its absorption. Clin Drug Investig 23:463–72
   PubMed Web of Science ®Google Scholar
• Rameis H. (1985). Quinidine-digoxin interaction: are the pharmacokinetics of both drugs altered? Int J Clin Pharmacol Ther Toxicol 23:145–53
   PubMed Web of Science ®Google Scholar
• Ramesh S, Kumar YS, Rao YM. (2006). Effect of ketoconazole on the pharmacokinetics of ornidazole – a possible role of p-glycoprotein and CYP3A. Drug Metabol Drug Interact 22:67–77
   PubMedGoogle Scholar
• Rao N, Dvorchik B, Sussman N, et al. (2008). A study of the pharmacokinetic interaction of istradefylline, a novel therapeutic for Parkinson’s disease, and atorvastatin. J Clin Pharmacol 48:1092–8
   PubMed Web of Science ®Google Scholar
• Rebello S, Compain S, Feng A, et al. (2011a). Effect of cyclosporine on the pharmacokinetics of aliskiren in healthy subjects. J Clin Pharmacol 51:1549–60
   PubMed Web of Science ®Google Scholar
• Rebello S, Leon S, Hariry S, et al. (2011b). Effect of verapamil on the pharmacokinetics of aliskiren in healthy participants. J Clin Pharmacol 51:218–28
   PubMed Web of Science ®Google Scholar
• Reitman ML, Chu X, Cai X, et al. (2011). Rifampin’s acute inhibitory and chronic inductive drug interactions: experimental and model-based approaches to drug-drug interaction trial design. Clin Pharmacol Ther 89:234–42
   PubMed Web of Science ®Google Scholar
• Rengelshausen J, Goggelmann C, Burhenne J, et al. (2003). Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin-clarithromycin interaction. Br J Clin Pharmacol 56:32–8
   PubMed Web of Science ®Google Scholar
• Sadeque AJ, Wandel C, He H, et al. (2000). Increased drug delivery to the brain by P-glycoprotein inhibition. Clin Pharmacol Ther 68:231–7
   PubMed Web of Science ®Google Scholar
• Sakugawa T, Miura M, Hokama N, et al. (2009). Enantioselective disposition of fexofenadine with the P-glycoprotein inhibitor verapamil. Br J Clin Pharmacol 67:535–40
   PubMed Web of Science ®Google Scholar
• Sansone-Parsons A, Krishna G, Martinho M, et al. (2007). Effect of oral posaconazole on the pharmacokinetics of cyclosporine and tacrolimus. Pharmacotherapy 27:825–34
   PubMed Web of Science ®Google Scholar
• Saruwatari J, Yasui-Furukori N, Niioka T, et al. (2012). Different effects of the selective serotonin reuptake inhibitors fluvoxamine, paroxetine, and sertraline on the pharmacokinetics of fexofenadine in healthy volunteers. J Clin Psychopharmacol 32:195–9
   PubMed Web of Science ®Google Scholar
• Schmitt C, Kaeser B, Riek M, et al. (2010). Effect of saquinavir/ritonavir on P-glycoprotein activity in healthy volunteers using digoxin as a probe. Int J Clin Pharmacol Ther 48:192–9
   PubMed Web of Science ®Google Scholar
• Schwarz UI, Gramatte T, Krappweis J, et al. (2000). P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans. Int J Clin Pharmacol Ther 38:161–7
   PubMed Web of Science ®Google Scholar
• Shimizu M, Uno T, Sugawara K, Tateishi T. (2006a). Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein. Br J Clin Pharmacol 61:538–44
   PubMed Web of Science ®Google Scholar
• Shimizu M, Uno T, Sugawara K, Tateishi T. (2006b). Effects of single and multiple doses of itraconazole on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein. Br J Clin Pharmacol 62:372–6
   PubMed Web of Science ®Google Scholar
• Shon JH, Yoon YR, Hong WS, et al. (2005). Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism. Clin Pharmacol Ther 78:191–201
   PubMed Web of Science ®Google Scholar
• Siedlik PH, Olson SC, Yang BB, Stern RH. (1999). Erythromycin coadministration increases plasma atorvastatin concentrations. J Clin Pharmacol 39:501–4
   PubMed Web of Science ®Google Scholar
• Skarke C, Jarrar M, Schmidt H, et al. (2003). Effects of ABCB1 (multidrug resistance transporter) gene mutations on disposition and central nervous effects of loperamide in healthy volunteers. Pharmacogenetics 13:651–60
   PubMedGoogle Scholar
• Smith DA, Koch KM, Arya N, et al. (2009). Effects of ketoconazole and carbamazepine on lapatinib pharmacokinetics in healthy subjects. Br J Clin Pharmacol 67:421–6
   PubMed Web of Science ®Google Scholar
• Soyinka JO, Onyeji CO. (2010). Alteration of pharmacokinetics of proguanil in healthy volunteers following concurrent administration of efavirenz. Eur J Pharm Sci 39:213–18
   PubMed Web of Science ®Google Scholar
• Spence R, Mandagere A, Richards DB, et al. (2010). Potential for pharmacokinetic interactions between ambrisentan and cyclosporine. Clin Pharmacol Ther 88:513–20
   PubMed Web of Science ®Google Scholar
• Sugimoto H, Hirabayashi H, Amano N, Moriwaki T. (2013). Retrospective analysis of P-glycoprotein-mediated drug-drug interactions at the blood-brain barrier in humans. Drug Metab Dispos 41:683–8
   PubMed Web of Science ®Google Scholar
• Tachibana T, Kato M, Takano J, Sugiyama Y. (2010). Predicting drug-drug interactions involving the inhibition of intestinal CYP3A4 and P-glycoprotein. Curr Drug Metab 11:762–77
   PubMed Web of Science ®Google Scholar
• Tachibana T, Kato M, Watanabe T, et al. (2009). Method for predicting the risk of drug-drug interactions involving inhibition of intestinal CYP3A4 and P-glycoprotein. Xenobiotica 39:430–43
   PubMed Web of Science ®Google Scholar
• Tapaninen T, Backman JT, Kurkinen KJ, et al. (2011). Itraconazole, a P-glycoprotein and CYP3A4 inhibitor, markedly raises the plasma concentrations and enhances the renin-inhibiting effect of aliskiren. J Clin Pharmacol 51:359–67
   PubMed Web of Science ®Google Scholar
• Tateishi T, Miura M, Suzuki T, Uno T. (2008). The different effects of itraconazole on the pharmacokinetics of fexofenadine enantiomers. Br J Clin Pharmacol 65:693–700
   PubMed Web of Science ®Google Scholar
• Tayrouz Y, Ganssmann B, Ding R, et al. (2001). Ritonavir increases loperamide plasma concentrations without evidence for P-glycoprotein involvement. Clin Pharmacol Ther 70:405–14
   PubMed Web of Science ®Google Scholar
• Terkeltaub RA, Furst DE, Digiacinto JL, et al. (2011). Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitors. Arthritis Rheum 63:2226–37
   PubMed Web of Science ®Google Scholar
• Tsuruoka S, Ioka T, Wakaumi M, et al. (2006). Severe arrhythmia as a result of the interaction of cetirizine and pilsicainide in a patient with renal insufficiency: first case presentation showing competition for excretion via renal multidrug resistance protein 1 and organic cation transporter 2. Clin Pharmacol Ther 79:389–96
   PubMed Web of Science ®Google Scholar
• Tuteja S, Alloway RR, Johnson JA, Gaber AO. (2001). The effect of gut metabolism on tacrolimus bioavailability in renal transplant recipients. Transplantation 71:1303–7
   PubMed Web of Science ®Google Scholar
• Tweedie D, Polli JW, Berglund EG, et al. (2013). Transporter studies in drug development: experience to date and follow-up on decision trees from the International Transporter Consortium. Clin Pharmacol Ther 94:113–25
   PubMed Web of Science ®Google Scholar
• Uno T, Shimizu M, Sugawara K, Tateishi T. (2006). Lack of dose-dependent effects of itraconazole on the pharmacokinetic interaction with fexofenadine. Drug Metab Dispos 34:1875–9
   PubMed Web of Science ®Google Scholar
• Vaidyanathan S, Camenisch G, Schuetz H, et al. (2008). Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: the role of P-glycoprotein in the disposition of aliskiren. J Clin Pharmacol 48:1323–38
   PubMed Web of Science ®Google Scholar
• van Haarst AD, Dijkmans AC, Weimann HJ, et al. (2009). Clinically important interaction between tedisamil and verapamil. J Clin Pharmacol 49:560–7
   PubMed Web of Science ®Google Scholar
• van Heeswijk RP, Bourbeau M, Campbell P, et al. (2006). Time-dependent interaction between lopinavir/ritonavir and fexofenadine. J Clin Pharmacol 46:758–67
   PubMed Web of Science ®Google Scholar
• von Hentig N, Muller A, Rottmann C, et al. (2007). Pharmacokinetics of saquinavir, atazanavir, and ritonavir in a twice-daily boosted double-protease inhibitor regimen. Antimicrob Agents Chemother 51:1431–9
   PubMed Web of Science ®Google Scholar
• Wacher VJ, Wu CY, Benet LZ. (1995). Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 13:129–34
   PubMed Web of Science ®Google Scholar
• Wason S, Digiacinto JL, Davis MW. (2012). Effect of cyclosporine on the pharmacokinetics of colchicine in healthy subjects. Postgrad Med 124:189–96
   PubMed Web of Science ®Google Scholar
• Wind S, Giessmann T, Jungnik A, et al. (2014). Pharmacokinetic drug interactions of afatinib with rifampicin and ritonavir. Clin Drug Investig 34:173–82
   PubMed Web of Science ®Google Scholar
• Winston A, Back D, Fletcher C, et al. (2006). Effect of omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteers. AIDS 20:1401–6
   PubMed Web of Science ®Google Scholar
• Wyen C, Fuhr U, Frank D, et al. (2008). Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients. Clin Pharmacol Ther 84:75–82
   PubMed Web of Science ®Google Scholar
• Yasui-Furukori N, Saito M, Niioka T, et al. (2007). Effect of itraconazole on pharmacokinetics of paroxetine: the role of gut transporters. Ther Drug Monit 29:45–8
   PubMed Web of Science ®Google Scholar
• Yasui-Furukori N, Uno T, Sugawara K, Tateishi T. (2005). Different effects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinetics. Clin Pharmacol Ther 77:17–23
   PubMed Web of Science ®Google Scholar
• Yoshizato T, Kotegawa T, Imai H, et al. (2012). Itraconazole and domperidone: a placebo-controlled drug interaction study. Eur J Clin Pharmacol 68:1287–94
   PubMed Web of Science ®Google Scholar
• Zimmerman JJ, Harper D, Getsy J, Jusko WJ. (2003). Pharmacokinetic interactions between sirolimus and microemulsion cyclosporine when orally administered jointly and 4 hours apart in healthy volunteers. J Clin Pharmacol 43:1168–76
   PubMed Web of Science ®Google Scholar